These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 22137729

  • 1. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Jan; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 3. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Nov; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 6. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 8. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E, Legendre C.
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [Abstract] [Full Text] [Related]

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 10. Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy.
    Kacar S, Gurkan A, Karaca C, Varılsuha C, Tilif S.
    Transplant Proc; 2010 Nov; 42(9):3513-6. PubMed ID: 21094806
    [Abstract] [Full Text] [Related]

  • 11. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 12. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Jan; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
    Sánchez-Escuredo A, Diekmann F, Revuelta I, Esforzado N, Ricart MJ, Cofán F, Torregrosa JV, Peri L, Ruiz Á, Campistol JM, Oppenheimer F.
    Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
    [Abstract] [Full Text] [Related]

  • 15. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 16. Late-onset proteinuria after antithymocyte globulin induction and de novo sirolimus monotherapy in kidney transplant recipients.
    Thomusch O, Tittelbach-Helmrich D, Seifert G, Pisarski P.
    Transplantation; 2011 Dec 15; 92(11):e62-3. PubMed ID: 22108426
    [No Abstract] [Full Text] [Related]

  • 17. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR.
    Transplant Proc; 2009 Sep 15; 41(7):2784-8. PubMed ID: 19765435
    [Abstract] [Full Text] [Related]

  • 18. Progression of graft fibrosis under mammalian target of rapamycin inhibitor-based regimen.
    Yilmaz M, Nart A, Sen S, Tasli F, Uslu A, Hur E, Ozkahya M, Hoscoskun C, Toz H.
    Nephrology (Carlton); 2010 Sep 15; 15(6):653-8. PubMed ID: 20883287
    [Abstract] [Full Text] [Related]

  • 19. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C.
    Expert Rev Clin Immunol; 2014 Feb 15; 10(2):295-305. PubMed ID: 24377908
    [Abstract] [Full Text] [Related]

  • 20. mTOR inhibitors in pediatric kidney transplantation.
    Pape L, Ahlenstiel T.
    Pediatr Nephrol; 2014 Jul 15; 29(7):1119-29. PubMed ID: 23740036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.